173 related articles for article (PubMed ID: 35213015)
1. Development and Use of Cellular Systems to Assess and Correct Splicing Defects.
Suárez-Herrera N; Tomkiewicz TZ; Garanto A; Collin RWJ
Methods Mol Biol; 2022; 2434():145-165. PubMed ID: 35213015
[TBL] [Abstract][Full Text] [Related]
2. Antisense Oligonucleotide-Based Rescue of Aberrant Splicing Defects Caused by 15 Pathogenic Variants in
Tomkiewicz TZ; Suárez-Herrera N; Cremers FPM; Collin RWJ; Garanto A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924840
[TBL] [Abstract][Full Text] [Related]
3. Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies.
Garanto A; Collin RWJ
Methods Mol Biol; 2018; 1715():61-78. PubMed ID: 29188506
[TBL] [Abstract][Full Text] [Related]
4. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
5. Antisense Oligonucleotide-Based Rescue of Complex Intronic Splicing Defects in
Corradi Z; Hitti-Malin RJ; de Rooij LA; Garanto A; Collin RWJ; Cremers FPM
Nucleic Acid Ther; 2024; 34(3):125-133. PubMed ID: 38800942
[TBL] [Abstract][Full Text] [Related]
6. Deep-intronic ABCA4 variants explain missing heritability in Stargardt disease and allow correction of splice defects by antisense oligonucleotides.
Sangermano R; Garanto A; Khan M; Runhart EH; Bauwens M; Bax NM; van den Born LI; Khan MI; Cornelis SS; Verheij JBGM; Pott JR; Thiadens AAHJ; Klaver CCW; Puech B; Meunier I; Naessens S; Arno G; Fakin A; Carss KJ; Raymond FL; Webster AR; Dhaenens CM; Stöhr H; Grassmann F; Weber BHF; Hoyng CB; De Baere E; Albert S; Collin RWJ; Cremers FPM
Genet Med; 2019 Aug; 21(8):1751-1760. PubMed ID: 30643219
[TBL] [Abstract][Full Text] [Related]
7. In vitro correction of a pseudoexon-generating deep intronic mutation in LGMD2A by antisense oligonucleotides and modified small nuclear RNAs.
Blázquez L; Aiastui A; Goicoechea M; Martins de Araujo M; Avril A; Beley C; García L; Valcárcel J; Fortes P; López de Munain A
Hum Mutat; 2013 Oct; 34(10):1387-95. PubMed ID: 23864287
[TBL] [Abstract][Full Text] [Related]
8. Antisense Oligonucleotide Rescue of Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin Synthase Gene.
Martínez-Pizarro A; Leal F; Holm LL; Doktor TK; Petersen USS; Bueno M; Thöny B; Pérez B; Andresen BS; Desviat LR
Nucleic Acid Ther; 2022 Oct; 32(5):378-390. PubMed ID: 35833796
[TBL] [Abstract][Full Text] [Related]
9. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
[TBL] [Abstract][Full Text] [Related]
10. Design of Bifunctional Antisense Oligonucleotides for Exon Inclusion.
Zhou H
Methods Mol Biol; 2022; 2434():53-62. PubMed ID: 35213009
[TBL] [Abstract][Full Text] [Related]
11. Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.
Gerard X; Garanto A; Rozet JM; Collin RW
Adv Exp Med Biol; 2016; 854():517-24. PubMed ID: 26427454
[TBL] [Abstract][Full Text] [Related]
12. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
13. Repair of aberrant splicing in growth hormone receptor by antisense oligonucleotides targeting the splice sites of a pseudoexon.
David A; Srirangalingam U; Metherell LA; Khoo B; Clark AJ
J Clin Endocrinol Metab; 2010 Jul; 95(7):3542-6. PubMed ID: 20427506
[TBL] [Abstract][Full Text] [Related]
14. Antisense modulation of both exonic and intronic splicing motifs induces skipping of a DMD pseudo-exon responsible for x-linked dilated cardiomyopathy.
Rimessi P; Fabris M; Bovolenta M; Bassi E; Falzarano S; Gualandi F; Rapezzi C; Coccolo F; Perrone D; Medici A; Ferlini A
Hum Gene Ther; 2010 Sep; 21(9):1137-46. PubMed ID: 20486769
[TBL] [Abstract][Full Text] [Related]
15. Antisense Oligonucleotide Screening to Optimize the Rescue of the Splicing Defect Caused by the Recurrent Deep-Intronic
Garanto A; Duijkers L; Tomkiewicz TZ; Collin RWJ
Genes (Basel); 2019 Jun; 10(6):. PubMed ID: 31197102
[TBL] [Abstract][Full Text] [Related]
16. Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides.
Igreja S; Clarke LA; Botelho HM; Marques L; Amaral MD
Hum Mutat; 2016 Feb; 37(2):209-15. PubMed ID: 26553470
[TBL] [Abstract][Full Text] [Related]
17. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
18. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
19. Proof-of-Concept: Antisense Oligonucleotide Mediated Skipping of Fibrillin-1 Exon 52.
Cale JM; Greer K; Fletcher S; Wilton SD
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801742
[TBL] [Abstract][Full Text] [Related]
20. Targeting Alternative Splicing for Therapeutic Interventions.
Centa JL; Hastings ML
Methods Mol Biol; 2022; 2537():21-36. PubMed ID: 35895256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
